Answers are grounded in this paper and cite their sources.
Purpose: Investigate the impact of treatments, including chemotherapy, radiotherapy, and chemoradiotherapy, on changing the carrying capacity of patient-derived tumor organoids (PDTOs). Methods: We proposed novel mathematical modeling frameworks based on the logistic/Gompertz models and the growth dynamics of PDTOs post-treatment. We cultured PDTOs from different patients and treated them with 4 Gy radiation, chemotherapy (FOLFIRINOX at a previously determined organoid-specific IC50 dose), and combined regimens, respectively. At least 10 organoids per group were tracked and measured using brightfield images up to 14 days following each treatment to capture organoid growth dynamics data, which was used for model calibration. The accuracy and robustness of the modeling were comprehensively evaluated by the average normalized mean squared errors (NMSE), Akaike Information Criterion (AIC), and Bayesian Information Criterion (BIC).Results: The logistic model with compression effects was selected as the optimal framework to describe organoid growth in the control group, enabling robust estimation of baseline carrying capacities. Under treatment, all modalities induced dynamic and patient-specific changes in carrying capacity. Chemotherapy exhibited dose-dependent and heterogeneous effects, ranging from transient stabilization and rebound at a low dose to rapid and sustained suppression at higher doses. Radiotherapy produced more consistent reductions across patients, albeit with distinct temporal profiles. Notably, combined chemoradiotherapy primarily led to rapid or substantial decreases in carrying capacity, stabilizing or enhancing the effects observed with single treatments, reducing inter-patient variability, and demonstrating a synergy effect that diminishes as drug levels increase. Conclusions: The results demonstrate that anticancer therapies modulate not only tumor size but also the underlying growth constraints (carrying capacities) in a dynamic and patient-specific manner. The proposed framework provides a novel perspective on tumor adaptation, resistance, regrowth, and a quantitative basis for understanding therapy-induced microenvironmental changes and long-term response; therefore, it holds promise for improving personalized treatment strategies and optimizing combination regimens.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: